Endo in a Bite

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Heart Failure Management (Episode 5)

In this episode, we review the 2026 Consensus Statement algorithm for heart failure management in adults with Type 2 Diabetes. Topics include the foundational role of SGLT2 inhibitors, heart failure with reduced and preserved ejection fraction, and evidence based pharmacologic therapy. We discuss dapagliflozin, empagliflozin, sotagliflozin, GLP-1 receptor agonists, and the role of semaglutide, tirzepatide, and liraglutide in different heart failure phenotypes. We also review medications that may worsen heart failure, including thiazolidinediones and selected DPP-4 inhibitors, therapeutic priorities for reducing hospitalization and cardiovascular mortality, and board relevant treatment recommendations, key clinical trials, and high yield facts to remember for exam preparation and clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Hypertension Management (Episode 4)

In this episode, we review the 2026 Consensus Statement hypertension algorithm for adults with Type 2 Diabetes. Topics include blood pressure targets, screening for secondary causes of hypertension, proper blood pressure measurement techniques, lifestyle interventions, and evidence based pharmacologic therapy. We discuss ACE inhibitors, ARBs, thiazide diuretics, calcium channel blockers, resistant hypertension management, mineralocorticoid receptor antagonists including spironolactone and finerenone, and the role of GLP-1 receptor agonists and SGLT2 inhibitors in blood pressure reduction. We also highlight board relevant treatment thresholds, cardiovascular risk reduction strategies, and key numbers to remember for exam preparation and clinical practice.

The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Lipid Management (Episode 3)

In this episode, we review the 2026 Consensus Statement on Lipid Management in Adults with Type 2 Diabetes. Topics include ASCVD risk assessment, LDL-C treatment targets, statin therapy, coronary artery calcium scoring, nonstatin lipid lowering therapies, triglyceride management, and key differences between ACC/AHA and AACE recommendations. We also discuss practical treatment strategies and board relevant pearls for cardiovascular risk reduction.

The 2026 Consensus Statement on Diabetes Classification in Adults (Episode 2)

In this episode, we review the 2026 Consensus Statement on Diabetes Classification in Adults. Topics include diagnostic criteria for diabetes, distinguishing type 2 diabetes from autoimmune, pancreatogenic, monogenic, endocrinopathy associated, and medication induced diabetes, and the role of phenotype, autoantibody testing, and C-peptide measurement in establishing the correct diagnosis. We also discuss key clinical features that should prompt reconsideration of a diabetes diagnosis and how accurate classification can guide appropriate treatment selection and improve patient outcomes.

The 2026 Consensus Statement on the Algorithm for Management of Adults With Type 2 Diabetes Classification (Episode 1)

In this episode, we review the latest 2026 Consensus Statement recommendations for the evaluation and management of prediabetes. Topics include updated diagnostic criteria, the recognition of prediabetes as a cardiometabolic disease state, lifestyle interventions as the foundation of therapy, and strategies to prevent progression to type 2 diabetes. We also discuss comprehensive cardiovascular risk reduction, weight loss goals, the role of anti obesity medications and bariatric surgery, evaluation of lean prediabetes, pharmacologic options for diabetes risk reduction, and key clinical pearls for optimizing long term patient outcomes. Learn how early identification and comprehensive management can reduce future diabetes and cardiovascular disease burden.